The Board of Malin Corporation plc is comprised of 5 Directors, of whom 1 has executive functions.
Ian Curley has had a long career in business. He was with Smurfit Kappa Group plc, a FTSE 100 company, for 26 years and served as its Chief Financial Officer. Most recently, he was the Chief Executive Officer of Ardagh Group S.A., during which time Ardagh listed on the New York Stock Exchange. Ian currently serves as a non-executive director of MidCap Financial, a specialist lender managed by Apollo. He is a graduate of University College Dublin , holds an MBA from the Michael Smurfit Graduate School of Business and is a Fellow of the Chartered Institute of Management Accountants
Dr. Adrian Howd has held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a Ph.D in molecular neuroscience from the University of London.
Rudy Mareel is a seasoned executive in the healthcare industry with significant strategic, operational, and change management experience in senior leadership roles and an in-depth understanding of the global healthcare market. Rudy has deep content expertise in medical nutrition; medical and pharmaceutical distribution; in vivo and in vitro diagnostics; medical technology; and, generic and bio-similar drug development & marketing. He also brings to bear an extensive network of scientific/technical and business leaders and key opinion leaders from across the globe. Finally, Rudy has served on Executive and Non-Executive boards – and as an advisor – to various companies doing business in the healthcare markets.
Dr. Jean-Michel Cosséry is a senior Healthcare Executive with global leadership experience in Research, Marketing and Commercial roles within Med-Tech and Pharmaceuticals. Jean-Michel spent 10 years at GE Healthcare as the Chief Marketing Officer and Vice-President Global Marketing. He represented GEHC at the GE Strategic Board level and he was a member of the board for the Wipro-GE Healthcare join venture in India.
More recently, Jean-Michel was with Eli-Lilly acting as Vice-President, North American Oncology, as well as Managing Director Northern Europe (including the UK and Ireland). Externally, Jean-Michel represented Lilly in the CEO Forum in Washington DC, was a board member of the ABPI and the Chairman of the Board of the American Pharmaceutical Group.
Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands. He received his PhD with honours in Nuclear Chemistry and Neurobiology from University Paris, France, and conducted post-doctoral research in Neuropharmacology at the NIH in the United States. Additionally, he holds a Pharm D with honours in Pharmacology from the University of Paris.
Liam Daniel is a non-executive director of Horizon Pharma plc since September 2014 and was President of the Institute of Directors in Ireland from 2013 to 2015 having been elected to the Board of that Institute in June 2010. He served with Elan from 1993 until 2014 in various roles including Controller, Company Secretary, Executive Vice President and as an Executive Director. Following Elan’s acquisition by Perrigo Company in December 2013, Mr. Daniel retired from Elan in March 2014. He is a graduate of University College Dublin, a Fellow of Chartered Accountants Ireland and a Chartered Director.